NasdaqCM:RNXT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	24	-2	N/A	N/A	3
12/31/2026	3	-14	N/A	-9	4
12/31/2025	1	-11	N/A	-9	4
9/30/2025	1	-11	-10	-10	N/A
6/30/2025	1	-11	-10	-10	N/A
3/31/2025	0	-10	-10	-10	N/A
12/31/2024	0	-9	-9	-9	N/A
9/30/2024	N/A	-9	-9	-9	N/A
6/30/2024	N/A	-8	-9	-9	N/A
3/31/2024	N/A	-8	-10	-10	N/A
12/31/2023	N/A	-10	-10	-10	N/A
9/30/2023	N/A	-9	-10	-10	N/A
6/30/2023	N/A	-10	-10	-10	N/A
3/31/2023	N/A	-10	-9	-9	N/A
12/31/2022	N/A	-10	-9	-9	N/A
9/30/2022	N/A	-10	-10	-10	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-6	-6	-6	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-4	-3	-3	N/A
12/31/2020	N/A	-4	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RNXT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: RNXT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RNXT is expected to become profitable in the next 3 years.

Revenue vs Market: RNXT's revenue (71.4% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: RNXT's revenue (71.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RNXT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/26 06:48
End of Day Share Price	2025/12/24 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RenovoRx, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Scott Henry	Alliance Global Partners
Edward Woo	Ascendiant Capital Markets LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.

RenovoRx Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Renovorx, Inc. Provides Revenue Guidance for 2026

No longer forecast to breakeven

Price target decreased by 7.1% to US$4.88

Forecast to breakeven in 2027

Price target increased by 29% to US$5.17

Recent updates

High number of new and inexperienced directors

Renovorx, Inc. Provides Revenue Guidance for 2026

RenovoRx, Inc. has filed a Follow-on Equity Offering in the amount of $3.723029 million.

RenovoRx, Inc. Appoints Timothy Donahue, Md to Scientific Advisory Board

RenovoRx, Inc. Announces Appointment of Thierry De Baère, Md, Phd to Its Scientific Advisory Board

RenovoRx, Inc.'s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

New minor risk - Share price stability

No longer forecast to breakeven

Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation

Renovorx, Inc. Appoints Philip Stocton as Senior Director of Sales and Market Development

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath®? Device to Solid Tumors

RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment

RenovoRx, Inc., Annual General Meeting, Jun 24, 2025

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

Revolutionizing Cancer Treatment

RenovoRx, Inc. announced delayed annual 10-K filing

Price target decreased by 7.1% to US$4.88

RenovoRx, Inc. Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Renovorx, Inc. Highlights Promising Pre-Clinical Data Abstract: Tamp™? Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx, Inc. has filed a Follow-on Equity Offering.

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Forecast to breakeven in 2027

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx, Inc.'s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx, Inc. Announces Publication of Positive Early-Stage Clinical Data Relating to its Trans-Arterial Micro-Perfusion Therapy Platform

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx, Inc. announced that it has received $11.136652 million in funding

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer

RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

Price target decreased by 23% to US$8.50

RenovoRx Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

RenovoRx, Inc. announced delayed 10-Q filing

RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial

RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Price target increased by 15% to US$11.50

Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Price target decreased to US$10.00

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

RenovoRx reports Q2 results

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Renovorx Appoints James Ahlers as Chief Financial Officer

RenovoRx names new finance CFO

Renovorx Launches "The Renovorx Story" Video Series

RenovoRx, Inc., Annual General Meeting, Jun 09, 2022

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing Tiger-Pac Phase 3 Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

RenovoRx, Inc. Receives New 510(k) Clearance for its RenovoCath Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx, Inc. has completed an IPO in the amount of $16.65 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies